We focused on five important and clinically actionable gene targets (EGFR (Exon 19 deletions, L858, and T790), BRAF (V600), and KRAS (G12/G13)), whose alterations are particularly relevant to lung cancer, melanoma, and colorectal cancer. Here, KRAS is linked to lung cancer.